 
The Combined Effects of Prolonged Sitting and Mental Stress on 
Vascular and Cerebrovascular Function in Middle- Aged Adults  
 
 
NCT number  [STUDY_ID_REMOVED]  
Document Date  12/19/2019  
 
Page 1 of 45 MASTER PROTOCOL 
 
The Combined Effects  of Prolonged Sitting  and Mental Stress on Vascular and 
Cerebrovascular Function in Middle- Aged Adults  
 
 
Principal Investigator  
 
[INVESTIGATOR_878009] & Sport Science  
306 Woollen Gym,  
UNC- CH 
Chapel Hill, NC [ZIP_CODE] 
 
Co-Investigator(s)  
Jake Diana  
[CONTACT_878041]:  None 
 
Version Date :  12/19/2019  
   
Page 2 of 45 PROTOCOL SYNOPSIS  
Study Title:  The Combined Effects of Prolonged Sitting and Mental Stress on 
Vascular and Cerebrovascular Function in Middle -Aged Adults  
Funding  UNC Department of Exercise & Sport Science  
Clinical Phase  Pi[INVESTIGATOR_878010] a public health risk through its effects on 
the cardiovascular system, and may lead to impaired whole -body 
cardiovascular health, which includes both vascular and 
cerebrovascular function. These effects may interact with other environmental variables, such as stress. However, no study has investigated the combined effect of a mental stressor and prolonged 
sitting on vascular and cerebrovascular function. The combined 
effect of prolonged sitting and mental stress may lead to an exacerbated effect on vascular, cerebrovascular, and executive function. We hypothesize that mental stress wi th the addition of 
prolonged sitting [SMS] will result in a greater increase in peripheral, central and cerebral arterial stiffness and elicit a decrease in cerebral perfusion, total blood flow to the brain, middle cerebral artery velocity and executive function, compared to mental stress without prolonged sitting [CON]. The findings from this study may result in a public health message regarding sedentary behavior and stress, and will help elucidate the mechanisms behind acute vascular, 
cerebrovascular, an d cognitive dysfunction during prolonged sitting.  
Study Objective(s)  To examine the cardiovascular response to mental stress with or 
without previous exposure to a bout of prolonged sitting .  
Study Design  Randomized Crossover Design, with two experimenta l conditions: 
without prolonged sitting + stress [CON] and with prolonged sitting 
+ stress [SMS].  
Participant  
Inclusion and Exclusion Criteria:  Inclusion  
• Male or female, aged 35 to 59 years Exclusion • Any known cardio- metabolic disorders  
• Taking medications known to affect cardiovascular function • Report cigarette smoking 
• Pregnant women  
Number of Participants  20 
Study Duration  1 year  
Study Phases   Familiarization:  to all devices  
CON: mental stress without prolonged sitting  
SMS: mental stress with prolonged sitting  
Design  Multi -visit randomized crossover trial  
Page 3 of 45 Primary & Secondary 
Outcomes Cerebrovascular  
Primary: Brain PWV  
Secondary: Executive Function & Neurovascular Coupling 
Vascular Primary: Brachial- Femoral PWV  
Secondary: Carotid -femoral PWV, femoral- ankle PWV, 
augmentation index, central blood pressures (cSBP, cDBP) 
Descriptive/ Mechanistic 
Outcomes Cerebrovascular:  
Cerebral Perfusion  
Middle Cerebral Artery Velocity  
Total Brain Blood Flow Static Cerebral Autoregulation  
 Vascular: Peripheral blood pressure Heart rate  
Baroreflex Sensitivity  
Heart Rate Variability  
Total hemoglobin  Tissue saturation index  
Accelerometer  
Statistical and Analytic 
Plan All statistical procedures will be competed with SPSS Statistics 
version 25.0 (SPSS, IN., Durham, NC, [LOCATION_003]) and Jamovi v0.9 (Jamovi, [LOCATION_006]). The α -level will be set a prior at 0.[ADDRESS_1226721] is required to  access.  
   
Page 4 of 45 CONTENTS  
PROTOCOL SYNOPSIS ................................................................................................................ 2 
ABBREVIATIONS  ........................................................................................................................ 7 
1  BACKGROUND AND RATIONALE  ................................................................................... 9 
Introduction and Rationale .......................................................................................................... 9 
1.1  Objective(s)  ..................................................................................................................... 9 
1.2  Aims  ................................................................................................................................ 9 
2  STUDY PROCEDURES  ...................................................................................................... 10 
2.1  Participa nts .................................................................................................................... 10 
Inclusion Criteria  .................................................................................................................. 10 
Exclusion Criteria  ................................................................................................................. 10 
2.2  Allocation to Treatment Groups and Blinding.............................................................. 10 
2.3  Experimental Design  ..................................................................................................... 10 
Study De sign ......................................................................................................................... 10 
Overview ............................................................................................................................... 10 
Experimental Set- Up ............................................................................................................. 12 
Familiarizatio n ...................................................................................................................... 12 
Experimental Visits  ............................................................................................................... 13 
2.4 Experimental Procedures .................................................................................................... 14 
Protocol 1: Mental Arithmetic Test  ...................................................................................... 15 
2.5  Measurements  ............................................................................................................... 16 
DEVICE 1: VICORDER®  ................................................................................................... 17 
DEVICE 2: Transcranial Doppler ......................................................................................... 17 DEVICE 3: Non -Invasive Blood Pressure (NIBP)  ............................................................... 17 
DEVICE 4: Doppler Ultrasound ........................................................................................... 17 DEVICE 5: Continuous Wave Near -Infrared Spectroscopy with Spatially Re solved 
Spectroscopy (cwNIRS -SRS or NIRS)  ................................................................................. 17 
DEVICE 6: ActiGraph  .......................................................................................................... 18 
DEVICES 7 & 8: Data Acquisition (PowerLab) and Data Processing (LabChart)  .............. 18 
C
ognitive Measurement 1: Trails A+B Tests  ....................................................................... 18 
Cognitive Measurement 2: Verbal Fluency Task ................................................................. 19 Cognitive Measurement 3: Memory Recall  .......................................................................... 19 
Cognitive Measurement 4: Brain Fog ................................................................................... 19 
Data Reduction ...................................................................................................................... 19 
Page 5 of 45 2.6 Timeline .............................................................................................................................. 20 
Study Time Commitment ...................................................................................................... 20 
Familiarization Session  ......................................................................................................... 21 
CON Experimental Session  .................................................................................................. 21 
SMS Expe rimental Session  ................................................................................................... 22 
3  MEASUREMENT DEVICES  .............................................................................................. 23 
Device 1: VICORDER®  ........................................................................................................... 23 
Device 2: Transcranial Doppler (TCD)  .................................................................................... 24 
Device 3: Non-Invasive Blood Pressure (NIBP) ...................................................................... 26 
Device 4: Doppler Ultrasound .................................................................................................. 27 Device 5: Continuous Wave Near -Infrared Spectroscopy with Spatially Resolved Spectroscopy 
(cwNIRS -SRS or NIRS)  ........................................................................................................... 29 
Device 6: ActiGraph  ................................................................................................................. 31 
DEVICES 7 & 8: Data Acquisition (PowerLab) and Data Processing (LabChart)  .................. 32 
4  STATISTICAL CONSIDERATIONS.................................................................................. 34 
4.1  Study Outcomes ............................................................................................................ 34 
4.2  Statistical Analysis  ........................................................................................................ 34 
4.3  Tabulation of Results .................................................................................................... 35 
4.4  Missing Values.............................................................................................................. 35 
4.5 Quality Control  ................................................................................................................... 36 
4.6  Sample Size  ................................................................................................................... 36 
4.7  Statistical Support  ......................................................................................................... 36 
5  Participant Screening, Withdrawal & Completion5 n failure procedures  ............................ 37 
5.2  Participant withdrawal  .................................................................................................. 37 
5.3  Participant Completion  ................................................................................................. 37 
6  SAFETY MONITORING & MANAGEMENT  ................................................................... 38 
6.1  Adverse Event Risk ....................................................................................................... 38 
6.2 Responding Adverse Events ........................................................................................... 39 6.3 Confidentiality ................................................................................................................ 39 
6.4 Participant Withdrawal ................................................................................................... 39 
7
 DATA COLLECTION AND MANAGEMENT  .................................................................. 40 
7.1  Quality Assurance ......................................................................................................... 40 
7.2  Database Security  .......................................................................................................... 40 
7.3  Confidentiality  .............................................................................................................. 40 
7.4  PHI Security  .................................................................................................................. 40 
Page 6 of 45 7.5  Risk of Deductive Disclosure ....................................................................................... 41 
7.6  Data Collection  ............................................................................................................. 41 
7.7 Data Entry  ..................................................................................................................... 41 
7.8  Data Editing  .................................................................................................................. 41 
7.9  Database Documentation  .............................................................................................. 41 
7.10  Pi[INVESTIGATOR_878011]  ....................................................................................... 41 
8 RECRUITMENT STRATEGYRECRUITMENT STRATEGY  .......................................... 42 
8.1 Recruitment Strategies  .................................................................................................. 42 
8.2  Recruitment Personnel  .................................................................................................. 42 
8.3  Protection of Privacy ..................................................................................................... 42 
8.4 Contact[CONTACT_878026]  ................................................................................................. 42 
8.4 Efforts to ensure equal access to participation among women and minorities ............. 42 
9 STUDY MANAGEMENT/ CONSENTSTUDY MANAGEMENT/ CONSENT  ............... [ADDRESS_1226722] (IRB) Approval .................................................. 43 
9.2 Efforts to Minimize Influencing the Participant’s Decision to Participate  ................... [ADDRESS_1226723]  Alzheimer’s Disease and Related Dementia  
AIx Augmentation Index  
APL  Applied Physiology Laboratory  
BF Blood Flow  
bfPWV  Brachial -Femoral Pulse Wave Velocity  
BP Blood Pressure  
CBP  Central Blood Pressure  
cfPWV  Carotid -Femoral Pulse Wave Velocity  
cm Centimeters  
CON  Control Experimental Session  
CONSORT  Consolidated Standards of Reporting Trials  
CV Cardiovascular  
CVD  Cardiovascular Disease  
CVH  Cardiovascular Health  
CVS  Cardiovascular System  
cwNIRS -SRS or NIRS  Continuous Wave Near -Infrared Spectroscopy  
DBP  Diastolic Blood Pressure  
ECG  Electrocardiogram  
EF Executive Function  
faPWV  Femoral -Ankle Pulse Wave Velocity  
HIPAA  Health Insurance Portability and Accountability Act  
HR Heart Rate  
hr Hours  
HRV  Heart Rate Variability  
ID Identification Number  
IRB Institutional Review Board  
kg Kilograms  
L Straight -line length or distance  
m/s Meters per second  
MAT  Mental Arithmetic Test  
MCA  Middle Cerebral Artery  
MCAv  Middle Cerebral Artery Velocity  
min Minutes  
mmHg  Millimeters of Mercury  
MS Mental Stress or Mental Stressor  
N/A Not Available  
NIBP  Non-Invasive Blood Pressure  
PA Physical Activity  
PCA  Posterior Cerebral Artery  
PHI Personal Health Information  
Page [ADDRESS_1226724] Velocity  
PWV/A  Pulse Wave Velocity and Analysis  
RDM  Research Database Management  
SBP Systolic Blood Pressure  
SD Standard Deviation  
sec or s  Seconds  
SMS  Sitting & Mental Stress Experimental Session  
TCD  Transcranial Doppler  
tHb Total Hemoglobin  
TMT  Trails Mental Tests or Trails A + B  
TSI Tissue Saturation Index  
TT or ΔT  Transit Time  
UNC  University of North Carolina at Chapel Hill  
US Ultrasound  
VFT  Verbal Fluency Test  
VPN  Virtual Private Network  
X Mean or Average  
  
Page 9 of 45 1  BACKGROUND AND RATIONALE  
Introduction and Rationale  
Prolonged sitting (PS) has gained attention over the past decade due to the sitting epi[INVESTIGATOR_878012].1,2 Participating in a sedentary lifestyle is common due to 
occupation, technology and vehicle transportation. Sedentary behavior (SB) has been shown to be a risk factor for cardiovascular disease (CVD) and  all-cause mortality. Additionally, a 
sedentary lifestyle has been linked to chronic cognitive dysfunction, thus playing a role in the appearance of Alzheimer’s Disease and Related Dementia’s (ADRD)
3. The av ailable research 
demonstrates that chronic SB is associated with a reduction in brain volume4 and a decline in 
cognition, in particular executive function (EF)5,6. Although, there is a level of uncertainty in the 
mechanism(s) connecting repeated acute SB exposure to chronic cerebrovascular complications.   In addition to cerebrovascular implications as a result of sedentarism and stress, central and 
peripheral cardiovascular function and structure are disrupted
7–9. In contrast to our understanding 
of cerebrovascular function, the physi ological mechanisms in which a mental stressor or a 
sedentary behavior like PS10–[ADDRESS_1226725] cardiovascular disruption as a result of PS that 
eventually leads to failures in regulatory mechanism that maintain healthy function11,13– 15. 
Repeated activation of neurohormonal pathways due to mental stress is known to impair 
cardiovascular health16,17. It is less clear how these negative stimuli impact the CVS acutely 
when experienced in combination. Developi[INVESTIGATOR_878013]
18–20 and economic 
productivity21. This study will provide new insights on the physiological mechanisms these 
health behaviors take to negatively change the responses of the CVS.   
1.1  Objective(s) 
To examine the card iovascular response to mental stress with or without previous exposure to a 
bout of prolonged sitting.   
1.2  Aims  
Two primary aims will be addressed:  
 
1. Explore the effects of mental stress with and without a bout of prolonged sitting on cerebrovascular function.  
2. Explore the effects of mental stress with and without a bout of prolonged sitting on vascular function. 
   
Page 10 of 45 2  STUDY PROCEDURES  
This study will be reported in accordance with Consolidated Standards of Reporting Trials 
(CONSORT) guidelines22.  
 
2.1  Participants  
We will recruit 20 adult  (35-59 y) male and female  participants . A healthy population sample 
will be recruited to mitigate the risk of age - or disease- related influences on the study outcomes. 
 
Inclusion Criteria  
• Male or female participants will be between the ages of 35-59 years old . 
 
Exclusion Criteria  
• Any known cardio- metabolic disorders  
• Taking medications known to affect cardiovascular function 
• Report drug or alcohol abuse 
• Report cigarette smoking  
• Pregnant women 
 
2.[ADDRESS_1226726] visit. This will be done during the familiarizatio n session using an online randomization software (www.randomizer.org). 
 
2.3  Experimental Design  
Study Design 
This study is a multi- visit (three in total) randomized crossover trial.  
 
Overview  
 During a single familiarization session, the research team will  obtain informed consent, and will 
describe to participants the purposes and procedures of this study. They will then be exposed to all experimental devices on  in a quiet, dimly lit and environmentally controlled room. 
Participants will return to the same location for  two experimental conditions  following these pre-
assessment guidelines:  
• Fasted (> 12 hours), consuming only water. 
• No caffeine consumption 12 hours prior to testing. 
• No vigorous exercise 24 hours prior to testing. 
• No alcohol consumption 24 hours prior to testing. 
      
Page 11 of 45 Table 1. Study Variables  
 Type  Measure  
Independent (Conditions)  Control (CON): Exposure to MS without PS  
 Sitting -Mental Stress (SMS): Exposure to MS after period of PS  
Primary Outcomes  Brain PWV  
 Brachial -femoral PWV  
Secondary Outcomes  Executive function  
 Neurovascular coupling  
 Carotid -femoral PWV  
 Augmentation index  
 Femoral -ankle PWV  
 
  
Page 12 of 45 Experimental Set -Up 
 
 
Figure 1. Experimental setup for to assess full body cardiovascular health. Each experimental 
device responsible for collecting data is shown in this pi[INVESTIGATOR_878014].  
 
Familiarization  
Participants will be familiarized with all experimental procedures and the n given the opportunity 
to ask any questions prior to providing written consents. Subjects will be brought to an upright, 
seated position using an Armedica AM353 Hi- lo Treatment Table (Tiger Medical, 
TIGER#TM83695) with feet flat on the ground with approximately 90 degrees of knee flexion. If feet cannot touch the ground, a platform will be used. The angle of recline of the chair will be measured, as well as the distance from the bottom of the chair to the ground to ensure equivalent chair placement for the  second visit. 
   

Page 13 of 45 Experimental Visits  
Refer to both Table 1 and Figure 1 for a breakdown of when experimental measures will be 
taken through both visits.  Participants will arrive to the  Applied Physiology Laboratory ( APL ) between 6:00 and 10:00 
AM fasted (for Visit 3: 2 -5 days following the Visit 2 ). Participants will be fasted and refrain 
from caffeine intake for at least [ADDRESS_1226727] in the supi[INVESTIGATOR_2547]  (white solid boxes in Figure 1 ). During these [ADDRESS_1226728] will be fitted with a NIRS probe on the prefrontal cortex  and medial 
gastrocnemius. The NIBP, TCD, and VICORDER® devices will also be affixed to the participant during this time period during this time. Sitting periods (solid gray boxes in Figure 1 ) 
will begin for both conditions once all devices are attached to the participant , the subject is 
shifted to an upright seated position, and at least 10min of supi[INVESTIGATOR_878015] . During 
the CON visit, subjects will undergo a brief 20min sitting period. For the SMS condition, subjects will be asked to sit stil l and quietly for 2 hours while watching a non- stimulating 
documentary. Each condition will receive the MS ( black  boxes in Figure 1 ) at the conclusion of 
the sitting periods in both CON and SMS. After exposure to the MS in both conditions, data collection procedures for this protocol will be completed  for VICORDER® immediately after the MS  and every 5 minutes for 25 minutes (See Figure 1  for visual details on how and when 
data is being collected). Brain BF will be assessed by [INVESTIGATOR_28936] [ADDRESS_1226729]-completion of the MAT . Finally, a battery of cognitive tests (Verbal Fluency Test and Trails A+B tests) will be 
administered to the participant (boxes with diagonal shades in Figure 1 ).  
  
Page 14 of 45 2.4 Experimental Procedures  
 
 
  
Figure 2. A visualization of the experimental protocol. Maintenance of external validity for this study will require exposure 
of the MS to be time -matched between both experimental conditions. The use of accelerometry will allow investiga tors to 
observe physical activity and sleep patterns to ensure uniformity in pre -assessment behaviors. All time points are expressed 
relative to the time of completion  of the mental stressor. Abbreviations : BF, blood flow; PWV/A, Pulse wave velocity & 
analysis; (1), collection of PWV/A for the primary outcome, bfPWV/A will be collected at this time point only; (3) 
collection of PWV/A for bfPWV, cfPWV, and faPWV; PA, Physical activity; t, time; NIRS, Near -infrared spectroscopy; 
NIBP, Non -invasive blood pressure; TCD, Transcranial Doppler.  
Page 15 of 45 Protocol 1: Mental Arithmetic Test  
 
Test Structure  Application  
 
 
  
 
• Test duration: Approximately 5min  
• Participant is in seated upright position  
• At the beginning of the test, the researcher 
will call out a four digit number and ask the participant to subtract either 7 or 13  
• Correct responses will not be recorded as an outcome for this study  • A metronome will play at a pre -set tempo. 
Subjects will be instructed to subtrac t 7 or 
13 for one minute from the original 
number continuously  
• Each minute, a new four digit number will 
be called out and the participant must 
subtract the [ADDRESS_1226730] (MAT), a commonly used exam to impose a small psychological stimulus on the participant. This test will approximately last for five minutes. The researcher will call out a four-digit number and as k the participant to subtract 
either seven or 13. Correct responses will not be recorded as an outcome for this study. During this test a metronome will play at a pre -set tempo. The subjects will be required to conduct 
continuous subtraction with the tempo to the best of their ability. Every minute, a new four digit number will be called out and the participant must subtract the seven or 13 from the number.         

Page 16 of 45 2.5  Measurements 
 
Table 2. Summarization of measures used for the protocol, “The Combined Effects of Prolonged 
Sitting and Mental Stress on Vascular and Cerebrovascular Function in Middle -Aged Adults”. 
Each experimental variable is listed under the “Outcomes” column with its design ation as either a 
primary, secondary, or mechanistic measure listed under the “Role Classification” column. The “Device” column names the equipment used to collect the data. Abbreviations: TCD, 
Transcranial Doppler; CON, Control condition; SMS, Sitting mental stress condition; VFT, Verbal fluency test; TMT, Trail making test; NIRS, Near- infrared spectroscopy; cwNIRS -SRS, 
Continuous- wave near -infrared spectroscopy. Minute values are expressed relative to the 
administration of the MAT.  
 
  
Page 17 of 45 DEVICE 1: VICORDER®  
PWV is calculated by [CONTACT_878027] (L) by [CONTACT_878028] (TT) between a 
proximal and distal arterial segment. Measurements for L are acquired by [CONTACT_878029], per manufacturer guidelines. For PWV measures including the carotid artery, the straight line distance from the carotid artery to the sternal notch is included in calculations for L.   Transit time is calculated by [CONTACT_878030]’s proprietary algorithm that measures the time between the foot of the proximal pressure waveform to the foot of the distal pressure waveform. Pressure waveforms will be simultaneously captured using volume displacement cuffs. A small balloon cuff is placed over the carotid artery. The balloon used to generate the carotid pulse wave does not cause discomfort as it inflates to sub -diastolic blood pressure (~50 mmHg). 
 
DEVICE 2: Transcranial Doppler  
Brain PWV and Middle cerebral artery velocity (MCAv) will be measured using con tinuous 
bilateral TCD (ST3, Spencer Technologies). MCAv accounts for 70- 80% of the brain’s total 
perfusion25. The data will be acquired continuously (50 Hz) using an analog- to digital convertor 
(PowerLab 30, ADInstruments).  
DEVICE 3: Non -Invasive Blood Pressure (NIBP)  
The PowerLab data acquisition system (PowerLab 30 series, ADInstruments, CO, [LOCATION_003] ) will be 
used to simultaneously acquire signals from each device and from ECG. A standard Lead II ECG will be recorded from three electrodes placed on the right and left shoulders, and just below the left rib. The signals from the ECG and two test devices  will be sampled a frequency was 1000 Hz, 
providing a temporal resolution of 1ms. 
 
DEVICE 4: Doppler Ultrasound  
A commercial ultrasound device equipped with 11- 3 MHz linear array probe will be used. 
Experimenters will assess blood flow in three cerebral arteries: common carotid, internal carotid, 
and vertebral.  
DEVICE 5: Continuous Wave Near -Infrared Spectroscopy with Spatially Resolved 
Spectroscopy (cwNIRS -SRS or NIRS)  
A continuous, non- invasive system to measure cerebral perfusion. The near -infrared spectroscopy 
probe used in this protocol emits a single frequency of light (cwNIRS) to monitor relative change 
in total hemoglobin. Using the spatially -resolved spectroscopy (SRS) technique, cwNIRS can 
estimate absolute measures of perfusion (e.g. t otal hemoglobin, tissue saturation index).  The 
cwNIRS -SRS device will be p ositions on the forehead, approximately 3cm to the right of the 
center, directly over the eyebrow. An additional probe will be placed over the medial gastrocnemius to observe venous pooling of blood in the lower -limbs. The location of both probes 
will be marked to ensure identical placement for the next experimental session. The device will be covered with a dark opaque cloth to prevent signal contamination by [CONTACT_878031].  
 
 
Page 18 of 45 
DEVICE 6: ActiGraph  
An ActiGraph accelerometer will be distributed to the research participant at the conclusion of the 
familiarization session along with a sleep journal packet. The subject will be asked to record on the timeline when he/she began to sleep and awaken each day until the conclusion of his/her participation in this study. The device will be worn on the individual’s non -dominant wrist 
according to manufacturer guidelines. The data collected from this device will be  used for one 
purpose: 
• Validate the subject’s compliance with pre- testing behavioral restrictions for the purpose 
of internal validity:  
o Waking up at similar times on the mornings of both experimental session  
 
DEVICES 7 & 8: Data Acquisition (PowerLab) and Data Processing (LabChart)  
For the TCD and NIBP, devices, data acquisition and processing will be automated using the accompanying software.   For the two test devices, the PowerLab data acquisition system (PowerLab 30 series, ADInstruments, CO, [LOCATION_003]) will be used to simultaneously acquire signals from each device and from ECG.   LabChart 8 (ADInstruments) will record and process the data acquired using PowerLab. The ECG signal does not require any post- processing, the software filters ensure a distinct R peak. The foot 
of the pressure waveforms from the NIBP and PPG devices will be identified using a standard second derivative function. Offline, a custom macro will identify the peak of the R wave and the peak of the second derivative of each pre ssure waveform, then calculate the time between said 
peaks.  
 
Cognitive Measurement 1 : Trails A+B Tests  
 
Test Structure & Application  
The Trail -Making Test – Part A, the circles are 
numbered 1 – 25, and the subject will draw 
lines to connect the numbers in ascending 
order. Part B presents numbers and letters 
placed in a semi -random fixed order, in such a 
manner to avoid overlappi[INVESTIGATOR_878016]. The subject will connect [ADDRESS_1226731] 
number ‘‘1’’ is followed by [CONTACT_878032] ‘‘A’’ 
followed by [CONTACT_878033] ‘‘2’’ then 
second letter ‘‘B’’ and so on23 Results for both 
TMT A and B will be reported in seconds.    
 
     
 
 
Page 19 of 45 Cognitive Measurement 2 : Verbal Fluency Task 
 
Test Structure  Application  
Tests of verbal fluency evaluate an 
individual’s ability to retrieve specific 
information within restricted search 
parameters24. The two subtests are (1) 
semantic fluency, and (2) phonemic 
fluency. The total number from e ach 
test will be summed and equate to the 
subjects’ cognitive performance.  
 
 
  
Cognitive Measurement 3: Memory Recall  
Participants will be read word lists from the Hopkins Verbal Learning Test at the rate of [ADDRESS_1226732] 
lists contain 12 words, 4 words from 3 semantic categories.  
 
Cognitive Measurement 4: Brain Fog 
Brain fog will be subjectively measured using a modified Borg Rate of Perceived Exertion (RPE) scale as there is no known reliable and valid objective measure of brain fog. This will be 
administered pre -test and post -cognitive testing period.  
 
Data Reduction 
The data collection periods are listed in Table 3. Minute values are noted in Figure 1  and are 
expressed relative to the administration of the MAT . 
 Table 3. Data reduction methods for experimental protocol  
Device  Outcomes  CON  (min)  SMS  (min)  Reduction  
VICORDER
® bfPWV  -5, 0, 5, 10, 
15, 20, [ADDRESS_1226733] is 
received from each 
participant from each 
experiental visit  
 
 
2.6 Timeline 
 
Study Time Commitment 
 
Stage  Time (mins)  Description  
Recruitment  10 Via email, flyer and/or class 
presentation  
Familiarization Session  [ADDRESS_1226734] with the 
purpose of the study, all 
experimental devices and the 
timeline of each experimental 
condition  
Experimental Visits  255 All measurements, single visit  
Total  300  
   
Page 21 of 45  
Familiarization Session  
Time (mins)  Action   
0:00-5:[ADDRESS_1226735] on the protocol and purpose of this study.  
5:00-10:00  Discuss the underlying physiology  and purpose that lead to the 
creation of this study. Discuss how this study will answer the research 
questions.  
10:00 -30:00  The researcher will attach each device to the participant to familiarize 
him/her to the protocol. No data will be collected for later analysis 
during this period.  
30:00 -35:[ADDRESS_1226736] and researchers will schedule the date and time  for CON and 
SMS. ActiGraph will be  attached to the research participant. A 
document will be provided detailing all behavioral restrictions (e.g. 
abstinence from caffeine, alcohol) and instructions on wearing the 
ActiGraph will be provided.   
Session End – Total time spent in APL : 35 minutes 
 
CON Experimental Session  
Time (mins)  Action  Measurement Order EXAMPLE START 
TIME  
-30:00 - -25:00 Anthropometrics  Weight (kg)  
Height (cm)  
BMI (km/m2) 10:15  AM 
-25:[ADDRESS_1226737]  N/A 10:20 AM 
-25:00 - -15:00  Affix devices to 
participant.  Path lengths (cm)  10:20  AM 
-15:[ADDRESS_1226738] . Begin 
continuous data 
collection from devices.  
Begin sitting period  TCD measures  
NIRS measures  
NIBP measures  
 10:30  AM 
-15:00 - -5:00 Ultrasound data 
collection  Cerebrovascular blood 
flow (common carotid, 
internal carotid, and 
vertebral arteries)  10:30  AM 
-15:00 - -5:00 VICORDER® data 
collection  bfPWV/A  
cfPWV/A  
faPWV/A  10:30 AM  
-5:00-0:[ADDRESS_1226739]  N/A 10:40 AM 
00:00-1:00 VICORDER® data 
collection  bfPWV/A immediately 
after MAT  10:45  AM 
5:00-20:00 VICORDER® data 
collection  bfPWV/A  every 5m post -
MAT for addition 20m  10:50 AM 
25:00-30:00 VICORDER® data 
collection  All measures of PWV/A 
10m post -MAT  11:10 AM 
30:00-40:00 Cognitive tests  Trails A+B  
VFT  11:[ADDRESS_1226740] End – Total time spent in APL: 75 minutes  
Page 22 of 45  
SMS Experimental Session  
Time (mins)  Action  Measurement Order  EXAMPLE  
START TIME  
-140:00 - -135:00 Anthropometrics  Weight (kg)  
Height (cm)  
BMI (k g/m2) 8:25 AM 
-135:[ADDRESS_1226741]  N/A 8:30 AM 
-135:00 - -125:[ADDRESS_1226742] 
path lengths required 
for measures from 
PWV/A  Path lengths (cm)  
8:30 AM 
-125:[ADDRESS_1226743] . 
Begin continuous data 
collection from devices. 
Begin prolonged 
sitting period  TCD  measures  
NIRS  measures  
NIBP  measures  
 8:40 AM 
 -120:00  -115:00 Ultrasound  data 
collection  Cerebrovascular blood flow 
(common carotid, internal 
carotid, and vertebral 
arteries)  8:45 AM 
-115:00 - -110:00 VICORDER®  data 
collection  bfPWV/A  
cfPWV/A  
faPWV/A  8:50 AM 
-20:00 - -15:00  Ultrasound  data 
collection  Cerebrovascular blood flow 
(common carotid, internal 
carotid, and vertebral 
arteries)  10:25 AM  
-15:00 - -5:00 VICORDER®  data 
collection  bfPWV/A  
cfPWV/A  
faPWV/A  10:30 AM  
-5:00 End prolonged sitting 
period  N/A 10:40 AM  
-5:00 – 0:[ADDRESS_1226744]  N/A 10:40 AM  
00:00-1:00 VICORDER® data 
collection  bfPWV/A immediately 
after MAT  10:45 AM 
5:00-20:00 VICORDER® data 
collection  bfPWV/A  every 5m post -
MAT for addition 20m  10:50 AM  
25:00-30:00 VICORDER® data 
collection  All measures of PWV/A 
10m post -MAT  11:10  AM 
30:00-40:00 Cognitive tests  Trails A+B  
VFT  11:[ADDRESS_1226745] End – Total time spent in APL: 180 minutes  
 
  
Page 23 of 45 3  MEASURE MENT DEVICES  
 
Device 1: VICORDER® 
 Device  
  
 
 • Company:  SMT Medical  
• Model:  VICORDER®: Arterial Stiffness 
Model 
• Location:  Wurzburg, [LOCATION_013]  
• Oscillometric cuffs inflate at sub- systolic 
pressures to detect changes in the pressure 
waveform.  
• Different sized cuffs are available.  
 Example Set -up  
 
 • The cuffs can be placed on any 2 arterial 
segments.  
• In the figure to the left, pressure cuffs placed 
over the brachial and femoral arteries.  
• A small balloon is placed over the carotid 
artery to obtain a measurement for cfPWV. A 
low pressure (50 mmHg) is u sed for this site 
with minimal discomfort.  Raw Data   
 
 • Top display = pressure waveform from 
proximal arterial segment 
• Bottom display = pressure waveform from 
distal arterial segment  
• Intrinsic software automatically detects the 
foot of the waveform of eac h arterial segment   
   Data Analysis  • A = Site of proximal artery  
• B = Site of distal artery  
• Pulse wave velocity (PWV)  = distance (D) / 
transit time (TT) 
• Straight line distance (L) = Distance 
between two cuffs as measured according to 
manufacturer guidelines  

Page 24 of 45  
 • Transit Time (ΔT or TT)  = Time between 
foot of proximal and distal waveforms.  
• Oscillometric pressure waveforms will be 
determined at the brachial artery of the non -
dominant arm using the VICORDER® in 
order to determine brachial and central 
arterial blood pressures.  Data Reduction  
 • L is plugged into software prior to 
measurement.  
• TT is averaged across 3 waveforms, and used 
to calculate one PWV  
• Process repeated 3 times, for 3 PWVs per 
measurement cycle.  
• Closest 2 PWVs averaged and used as 
outcome for measurement cycle.  
  
Device 2: Transcranial Doppler (TCD)   Device   
 
 • Company:  Compumedics DWL  
• Model:  Transcranial Doppler Sonography 
TCD  
• Location: Charlotte  NC, US A 
 
• DiaMon headset can be adjusted in 3 ways to 
accommodate each individual  
• Connection between rear band and side panel 
sits behind the ear, below the occipi[INVESTIGATOR_878017] 
• TCD probes should be in contact [CONTACT_878034] -up  
 
 • Ensure probe is positioned over the temporal 
window 
• Apply ultrasound gel to probe and/ or 
temporal window 
• Move probe until faint trace appears and then 
make further fine movements to increase trace 
of artery velocity  

Page 25 of 45 Raw Data   
 
 • Signal quality is indicated by [CONTACT_68458]: the more 
yellow, the stronger the signal  
• Gain and depth adjust can be made in the 
signal window. Gain should sit between 38- 44 
for optimal signal output 
• Typi[INVESTIGATOR_878018] 
(MCA) are ~80 cm/s -1, and ~60 cm/s -1 in 
older populations 
• Typi[INVESTIGATOR_878019] 45-55 
 Data Analysis  
 
 • Using a custom macro, the software (Labchart) 
identifies the peak of the ECG R - wave and the 
peak of the second derivative of each pressure 
waveform (corresponds to foot), then calculate the 
transit time (TT) between said peaks.  
• Pulse wave velocity (PWV) = distance (L) / TT  Data Reduction  
 • Measures of brain PWV, MCA velocity, static 
CA and neurovascular coupling will be  
collected from this device are continuously 
recorded during a testing session  
• Data reduction for this protocol will require 
the selection of 30s epochs at specific time 
points to observe how PS and MS are 
impacting measures of CVH  
• In the pi[INVESTIGATOR_878020], a researcher selected 
a time period to report the data collected 
during this time.  
• A strict protocol will be followed to ensure 
that selection of 30s epochs are synchroni zed 
amongst all measures and research 
participants to prevent bias.  
 
          

Page 26 of 45 Device 3: Non-Invasive Blood Pressure (NIBP )  Device   
 
 • Company:  ADInstruments  
• Model:  Human NIBP Nano System , 
Finapress  
• Location:  Sydney, Australia 
• Single cuff contains an infrared 
photoplethysmographic (940 mm Hg) sensor 
and inflatable cuff.  
• PPG sensor continuously captures the pulse 
waveform.  
• Inflatable cuff used to calibrate waveform  
• Height correction unit corrects for 
hydrostatic pressure changes due to change  in 
hand position relative to the heart.  Example Set -up  
 
 • Device placed between distal and proximal 
inter- phalangeal joint of the index finger.  
• Wrist apparatus is strapped to the individual’s 
non-dominant wrist  Raw Data   
 
• Data captured using a data acquisition system ( PowerLab ). 
• Also displayed are electrocardiogram (ECG) signals captured by [CONTACT_878035].  

Page 27 of 45 Data Analysis 
 
• LabChart 8 can perform real time or offline function, including data averaging, peak 
detection, derivates etc.  Data Reduction 
  
 
 • All measures collected from this device are 
continuously recorded during a testing 
session  
• Data reduction for this protocol will require 
the selection of 30s epochs at specific time 
points to observe how PS and MS are 
impacting measures of CVH  
• In the pi[INVESTIGATOR_878020], a researcher selected 
a time period to report the data collected 
during this time.  
• A strict protocol will be followed to ensure 
that selection of 30s epochs are similar 
amongst all measures and research 
participants to prevent bias.  
 
Device 4: Doppler Ultrasound   Device   
 
 • Company:  GE Healthcare  
• Model:  Logiq P6  
• Location:  Chicago, IL 
• An 11L linear probe will be used for this 
protocol 

Page 28 of 45 Example Set -up  
 
 • Measurement of blood flow through the 
carotid artery using a linear probe 
• Probe is placed parallel to the blood vessel 
• 10s videos of the common carotid, vertebral, 
and internal carotid arteries will be collected 
at each designated time point in the protocol 
• Participants will be instructed to hold one’s 
breath for the duration of the recording to 
ensure a clear video will be captured of the observed artery Raw Data   
 
  
• Ultrasound videos are recorded at 30 Hz 
using an external video capture system  
• Debut Professional (v4.0, NCH Software®) is used to record the present image on the Ultrasound device for later analysis  
• Image to the left shows an example video 
captured by [CONTACT_11377] s software Data Analysis 
  
• The captured videos will be analysed offline 
using specialized image analysis software 
(FMD Studio®,) shown to the left.  
• The software measures and exports second -
by-second diameters and blood velocities 
• Cardiovascular Suite (Quipu, v3.5.3) 
analyzes raw ul trasound footage 
• Coordination with ECG  will produce 
measures of blood flow Data 
Reduction   

Page 29 of 45  
 
• Lab-designed macro cleans raw data output generated by [CONTACT_878036] 
• Macro is capable of calculating blood flow along with other measures that define the 
flow profile of the observed artery  
 
Device 5: Continuous Wave Near -Infrared Spectroscopy with Spatially Resolved 
Spectroscopy (cwNIRS -SRS or NIRS)   Device   
 
 • Company:  Artinis Medical Systems  
• Model:  Portalite  
• Location:  Amsterdam, Netherlands 
• Two probes will be used in this protocol 
o Cerebral perfusion: placed over 
the frontal cortex  
o Lower -limb perfusion: placed 
over the muscle belly of the gastrocnemius Example Set -up  
 
 • Researchers will follow manufacturer 
guidelines on appropriate probe placement 
• An opaque cloth (not shown) will be wrapped 
over the probe to prevent the influence of 
ambient light on infrared signals  
• For NIRS probe placement over the 
gastrocnemius: An 11L linear probe from the Logiq 6 ultrasound device wil
l be used to 
ensure the NIRS device is not placed over a blood vessel. 
• The ultrasound device is only be used to 
ensure the probe is being placed only over the 
muscle belly of the gastrocnemius  

Page 30 of 45 Raw Data   
 
 
• Oxysoft, a proprietary software system developed by [CONTACT_173408], will be 
used to collect and display raw data 
• Displayed are three signals each for total hemoglobin (greens), oxygenated hemoglobin (reds), and deoxygenated hemoglobin (blues)  
 Data Analysis  
 • The NIRS devices emits three separate 
wavelengths to capture different depths of the  
• The spatially resolved signal working with 
the probe is capable of estimating absolute 
values for each variable used in this protocol  Data Reduction  
 
 • A lab -designed macro will export the raw 
data to an Excel sheet  
• Column 1 represents the time point  
• A researcher will then select 30s sections for specific time points during the experimental conditions (e.g. immediately post -
MAT, [ADDRESS_1226746]- MAT)  
 

Page 31 of 45  
Device 6: ActiGraph   Device   
 
 • Company:  ActiGraph  
• Model:  wGT3X- BT 
• Location:  Pensacola, FL  
 Example Set -up  
 
 
 
 • Device is worn on the non -dominant wrist  
• To maintain internal validity subjects will be 
asked to complete a sleep journal that details 
when the ActiGraph device is being worn, 
when the participant goes to sleep, and when 
he/she awakens.  
• This information will only be used to validate the adherence of the participant to pre- test 
behaviors: Waking up at relatively the same 
time of the morning, no vigorous exercise 
24hr prior  

Page 32 of 45 Raw Data   
 
 
 
 • Upper image: 24 hour observation of counts 
of physical activity and ambient light 
throughout several days 
• Lower image: More detailed view of physical 
activity counts.  
  Data Analysis  
 
 • Trained researchers will use the returned 
sleep journal to set cut points for the 
beginning and end of sleep periods of the research participant  
• This process allows more accurate reports of 
ambient physical activity before and during 
experimental sessions  Data Reduction  
 
• Data can be reduced on an hourly or daily basis 
• Accelerometry data separates daily ambulation into different categories: sedentary, 
light, moderate, and vigorous  
  
DEVICES 7 & 8: Data Acquisition (PowerLab) and Data Processing (LabChart) 
 Device   
 
 • Company: ADInstruments  
• Model: PowerLab 8/35 
• Location: Sydney, Australia 
• Device will work in conjunction with 
LabChart software and NIBP cuff  

Page 33 of 45 Example Set -up  
 
 • Example set -up shown to an in the image to 
the left. Shown in this example:  
o Upper left: EKG  
o Bottom PowerLab Unit: TCD inputs 
for eventual display on LabChart  Raw Data   
 
 • Shown is LabChart receiving the signals 
interpreted by [CONTACT_878037]  • LabChart 8 can perform real time or offline function, including data averaging, peak 
detection, derivates etc.  Data Reduction 
  
 
 • After the completion of a data collection set, 
summarized data is calculated by [CONTACT_183768]  
• Data will be exported to lab Excel files for 
comparison amongst subjects and final 
analysis 
  

Page 34 of 45 4  STATISTICAL CONSIDERATIONS  
4.1  Study Outcomes  
The study outcomes ar e listed below.  
 
The primary outcomes are: 
• Brain PWV  
• Brachial -femoral PWV  
 Note: All power calculations for this protocol are based on measures from PWV  The secondary outcomes are:  
• Executive function  
• Neurovascular coupling 
• Carotid -femoral PWV  
• Augmentation index 
• Femoral- ankle PWV  
Mechanistic and descriptive outcomes are:  
• Cerebral perfusion  
• Total brain  blood flow 
• Middle cerebral artery velocity  
• Static cerebral autoregulation  
• Baroreflex sensitivity  
• Heart rate variability  
• Heart rate  
• Peripheral diastolic blood pressure  
• Peripheral systolic blood pressure 
• Tissue saturation index  
• Venous pooling in the gastrocnemius 
• Bouts of physical activity 
• Sleep duration 
 
4.2  Statistical Analysis  
All statistical procedures will be competed with SPSS Statistics version 25.0 (SPSS, IN., Durham, NC, [LOCATION_003]) and Jamovi v0.9 (Jamovi, [LOCATION_006]). The α -level will be set a prior at 0.[ADDRESS_1226747] the sample group and to eliminate the potential for extraneous covariates. Answering the research question will require a linear multi- level mixed model . 
Statistical models will observe for changes in the primary and secondary outcomes within conditions (Baseline, Post- PS, Post -MS) and between conditions (CON vs. SMS at similar time 
points). Mechanistic outcomes will also be used to assist in discussions of physiological responses to MS and PS.  Effect sizes  will be calculated as Cohen’s d, where <0.20 is considered 
to be a small, > 0.20 to < 0.50 a moderate, and > 0.[ADDRESS_1226748]. For the mixed models Cohen’s d will be calculated as the effect of condition (β) or time (β) from linear mixed models divided by [CONTACT_878038]. Raw data will be presented as mean [standard deviation] and mixed model data are presented as mean [95% confidence interval].  
Page 35 of 45 4.3  Tabulation of Results  
Mean and variance will be tabulated after raw measures taken in triplicate are entered into a lab -
created template.   
 
Table 4. Methods to describe result summarization for this experimental protocol. Abbreviations:  X, Mean/SD will be calculated for this result; 1, Measure is reported as a single 
value from each experimental visit; n/a, Measure is not being taken at this timepoint.  
 
4.[ADDRESS_1226749]-MS 
Device  Outcomes  X SD X SD X SD 
VICORDER
® bfPWV  X X X X X X 
 cfPWV  X X X X X X 
 faPWV  X X X X X X 
 CBPs  X X X X X X 
 Peripheral BPs  X X X X X X 
 Augmentation 
index  X X X X X X 
TCD  Brain PWV  X X X X X X 
 MCA velocity  X X X X X X 
 Static cerebral 
autoregulation  X X X X X X 
 Neurovascular 
coupling  X X X X X X 
NIBP  Baroreflex 
sensitivity  X X X X X X 
 Heart rate 
variability  X X X X X X 
 Heart rate  X X X X X X 
Ultrasound  Cerebrovascular 
BF 1 X 1 X 1 X 
NIRS  Cerebral perfusion  X X X X X X 
 Tissue saturation 
index  X X X X X X 
 Venous pooling  X X x X x X 
Cognitive 
Tests  Executive 
Function  n/a n/a n/a n/a [ADDRESS_1226750] three research participants will 
be checked by [CONTACT_446694].   At the conclusion of the study, a random selection of 10% of the data sets (e.g., all data from 2 participants) will be re -scored by [CONTACT_878039] -observer 
reliability.  
 
4.[ADDRESS_1226751] velocity (PWV). We will conduct a power calculation based on reported normal values for the primary outcome, central PWV. Healthy people aged 40-49 maintain an average PWV of 7.5 m/s. For the current study, we will opt to sample based on a conservative change score of 1 m/s. We will also use a conservative usual error of 1.25 m/s based on reported data. Using magnitude- based inference, to estimate the sample size required to 
detect the smallest detrimental (or beneficial) effect in a cross -over study, with the maximum 
chances of a type 1 and 2 error set at 5% (i.e. very unlikely), approximately eighteen participants will be required.  
 
4.7  Statistical Support 
Statistical expertise, study coordination and statistical computations for research database management (RDM) and data analysis will be provided by [CONTACT_5051]. Advised by [CONTACT_878040], PhD. If needed, the faculty advisor will submit a request to NCTracs.    
Page 37 of 45 5  Participant Screening, Withdrawal & Completion 5 n failure procedures  
Participants will not be able to participate if they do not meet the inclusion criteria. The 
acceptability of participants’ potential recordings from each device will be made during the 
familiarization visit.  
 
5.[ADDRESS_1226752] the participant by [CONTACT_353197] a personal visit to establish the reason for the study withdrawal. A complete final evaluation at the time of the patient’s study withdrawal should be made with an explanation of why the patient is withdrawing from the study. If the reason for removal of a patient from the study is an adverse event, the principal specific event will be record ed on study 
data collection forms. If the reason for withdrawal or removal is not an adverse event, the nature of the reason will be recorded on the study data collection forms.  
5.3  Participant Completion  
Upon completion of the study, participants will b e thanked, and the results discussed.  
  
Page 38 of 45 6  SAFETY MONITORING & MANAGEMENT  
 
6.[ADDRESS_1226753] occurred with use of the stated devices.  
 VICORDER® - The system requires the placement of pressure cuffs over several arteries for the collection of PWV/A data. Pressure cuffs will only be inflated underneath a l evel of 65 
mmHg. Physical harm or discomfort is unlikely and include, but are not limited to:  
 
• Risk 1: Discomfort/unease: Infrequent (1 – 10%)  – Application of a slight pressure over 
the carotid artery may impose a sense of unease for the participant. How ever, the light 
pressure used for this experimental protocol will in no way significantly damage 
cardiovascular structure or place the participant in danger. Investigators will make certain that communication on the procedures during testing session are clearly conveyed to the participant for comfort and safety.  
 Near -infrared spectroscopy (NIRS): Risk of injury or discomfort is extremely low due to this 
device. Possible physical harms are, but not limited to: 
• Risk 1: Eye damage/irritation : Rare (<1%)  – Please do not, at any point, stare into the 
light emitted from the NIRS probe  
• Risk 2: Skin heating and irritation : Rare (<1%) – Wearing the NIRS probe for extended 
periods of time at once can theoretically lead to a warm feeling at the area where the probe is placed. However, this risk is minimal because the light emitted from this probe is 
not powerful enough to heat the skin. If you let the investigators know of any discomfort due to the probe, we will follow manufacturer guidelines to ensure the devic e is 
functioning correctly.  
Transcranial Doppler (TCD): Data collection from this system requires the affixation of a headpi[INVESTIGATOR_878021]. Risk of injury due to this device is extremely low. Possible harms may include, but are not limited to:  
• Risk 1: Mild headache : Infrequent (1 – 10%)  – High quality data from this device 
requires the placement of the probe over the middle cerebral artery (MCA) and posterior 
Page 39 of 45 cerebral artery (PCA). The slight pressure applied to the area may be slightly 
discomforting and unusual for the participant. 
6.[ADDRESS_1226754] sustains an injury throughout the duration of the study, they will be referred to the appropriate medical personnel on the UNC campus (i.e. Campus Health Services or the UNC Hospi[INVESTIGATOR_678663]). In the occurrence of a rare adverse event, all members of the research team are CPR/AED certified so that they can provide the proper care to the Participant. A member of the research team will be with the Participant the whole time while in the research lab and [ADDRESS_1226755] access are exercise physiology professors, Ph .D. candidates, and master’s  
candidates, and selected undergraduate students who are directly associated with the study and have performed all necessary trainings regarding sample handling, laboratory procedures, and confidentiality. All participants within the study are coded with an individual ID and no names will be identified in any document besides a master key document. This master key document will be kept in a locked drawer in the Applied Physiology Research Lab. No subjects will be identified in any report or publication of this study.  
6.[ADDRESS_1226756] overall responsibility for the 
definition and production of the documents necessary to describe all aspects of the study in sufficient detail to ensure the study can be conducted in a scientifically sound, standardized manner. The PI  [INVESTIGATOR_878022].  
7.2  Database Security  
The database will be created within centralized files and maintained on University approved; password protected, encrypted, shared research drives in the orthopedic surgery department and viewed only on approved devices by [CONTACT_371194]. Collected data will be kept in a locked cabinet in the Applied Physiology Lab in Fetzer Hall on the University of North Carolina at Chapel Hill campus. Only members of the research team will have keys for this cabinet. All 
shared files between the research team will be stored on a UNC file requiring an Onyen Login and either a UNC computer or UNC campus VPN.  
 
7.3  Confidentiality  
Resear ch data will be identified only by [CONTACT_776322] (IDs). These study IDs will 
be used to maintain relationships in the data between various tables. All consent forms and any paper data collection instruments will be stored in a locked cabinet in a secure location. The list identifying subjects with their contact [CONTACT_776323]. No participants will be identified in any report or publication of this study. Participants will be identified via identification code for data collection purposes. All electronically collected data will be stored on a computer that only team members  Onyen password will allow access to study 
information. This computer will be located in the  Graduate Student Office of the Applied 
Physiology Laboratory at the University of North Carolin a at Chapel Hill. Data analysis 
procedures will be performed on secure computers within  Fetzer Hall, with which password is 
required to access.  
 
7.[ADDRESS_1226757] of 1996 (HIPAA). Procedures to maintain privacy and confidentiality will be followed rigorously. Each research 
Page [ADDRESS_1226758] w ill be assigned a study identification number (ID). The scientific study data will be 
stored in a digital file that does not include patient identifiers or personal health information 
(PHI). A separate data file will contain identifiers and PHI. A master f ile linking patient 
identifiers to the study data will be kept under lock and key by [CONTACT_22660]. The database will be password protected and will be stored on servers housed in a secure location. 
 
7.[ADDRESS_1226759]'s identity and responses.  
 
7.[ADDRESS_1226760] tab (Tab 3) represents the difference in Tab 1 and 2. If values are not 0, the second person will find and fix data.  
 
7.8  Data Editing  
The PI  [INVESTIGATOR_878023] -monitoring results and investigating questio ns 
raised (i.e., queries) about remarkable or questionable data values.  
 
7.9  Database Documentation 
The names of the variables and their valid ranges or categorical values will be listed in a “data book”. Documentation will also include an index of computer programs and an index of reports. All programming for statistical computation will include comments providing internal documentation.  
7.[ADDRESS_1226761] operation will be pi[INVESTIGATOR_878024], materials and systems prepared. Every clinical study collects such pi[INVESTIGATOR_10299] –either intentionally prior to commencement of the study, or unintentionally after recruitment has begun.     
Page 42 of 45 8 RECRUITMENT STRATEGYRECRUITMENT STRATEGY  
8.1 Recruitment Strategies  
Participants will be recruited via email, flyer and/ or  workplace presentation from working class 
individuals in the Raleigh -Durham- Chapel Hill area. Given that we are targeting a fairly general 
population, and only a limited number of participants are being recruited, we believe there is a 
high likelihood of having access to the projected number of individuals. 
 
8.2  Recruitment Personnel  
Recruitment will be conducted by [CONTACT_978] [INVESTIGATOR_878025]’s  students listed on this 
application. The team will not recruit students who are currently enrolled in a class they are responsible for.  
 
8.[ADDRESS_1226762] equal access to these places and will thus be given equal access to volunteer as  
subjects. Pregnant women will be excluded from the initial study to limit the variation seen within subjects.   
Page 43 of 45  
 
9 STUDY MANAGEMENT/ CONSENTSTUDY MANAGEMENT/ CONSENT  
9.[ADDRESS_1226763] (IRB) Approval 
Before recruitment and enrollment into this study, the patient will be given a full explanation of the study. A member of the research team will cover each section of the consent form in detail with the subject. At the end of each section, the research team will ask the subject if he or she has any questions. Once the entire consent form is described to the subj ect, the subject will be 
reminded that they may withdraw from the study at any time without repercussion. After all questions have been exhausted and the subject agrees to participate, the subject will sign the consent form in the presence of a research team member. Data collection will begin only if the subject has signed an informed consent form.  
9.2 Efforts to Minimize Influencing the Participant’s Decision to Participate  
During screening and familiarization,  the subject will be allowed to ask any quest ion about the 
study while the consent form is being explained. The subject will sign the consent form after it has been described in full and all study- related questions answered. If subjects need additional 
time to decide, it will be granted. It will be made clear to the subject that signing of the consent form does not bind the subject to participation in the study and if at any time he or she wishes to withdraw from the  study, he or she may do so without repercussion. 
 
9.2 Required Documentation  
Before t he study can be initiated at any site, the following documentation will be placed on file at 
the University of North Carolina : 
• A copy of the official IRB approval letter for the protocol and informed consent  
• A copy of the IRB- approved consent form  
 
9.3 Adherence to the Protocol  
Except for an emergency situation in which proper care for the protection, safety, and well-being of the study patient requires alternative treatment, the study shall be conducted exactly as described in the approved protocol.    
9.4 Emergency Modifications 
Members of the research team will inform participants of the study protocol and any potential 
risk. They will then sign an informed adult consent form included in the IRB. As mentioned previously, subjects will be properly treated and cared for in the unlikely event of an emergency or adverse reaction to any of the noninvasive treatments or venous blood draws.    
Page 44 of 45 10 REFERENCESREFERENCES   
 
1. Owen, N., Healy, G. N., Matthews, C. E. & Dunstan, D. W. Too much sitting: The population health science of sedentary behavior. Exerc. Sport Sci. Rev.  (2010). 
doi:10.1097/JES.0b013e3181e373a2 
2. Ng, S. W. & Popkin, B. M. Time use and physical activity: A s hift away from movement 
across the globe. Obes. Rev.  (2012). doi:10.1111/j.1467-789X.2011.[ZIP_CODE].x 
3. Dishman, R. K. et al.  Neurobiology of exercise. Obesity (2006). doi:10.1038/oby.2006.46 
4. Siddarth, P., Burggren, A. C., Eyre, H. A., Small, G. W. & Merrill, D. A. Sedentary behavior associated with reduced medial temporal lobe thickness in middle -aged and older adults. 
PLoS One  (2018). doi:10.1371/journal.pone.0195549 
5. Edwards, M. K. & Loprinzi, P. D. The Association Between Sedentary Behavior and Cognit ive Function Among Older Adults May Be Attenuated With Adequate Physical 
Activity. J. Phys. Act. Heal. (2016). doi:10.1123/jpah.2016-0313 
6. Hamer, M. & Stamatakis, E. Prospective study of sedentary behavior, risk of depression, and cognitive impairment. M ed. Sci. Sports Exerc.  (2014). 
doi:10.1249/MSS.0000000000000156 
7. Antle, D. M., Cormier, L., Findlay, M., Miller, L. L. & Côté, J. N. Lower limb blood flow and mean arterial pressure during standing and seated work: Implications for workplace posture reco mmendations. Prev. Med. Reports 10, 117–122 (2018). 
8. Credeur, D. P. et al.  Impact of Prolonged Sitting on Peripheral and Central Vascular Health. 
Am. J. Cardiol. (2018). doi:10.1016/j.amjcard.2018.10.014 
9. Thosar, S. S. Prolonged Sitting, Oxidative Stress and Vascular Function. (2014). 10. Morishima, T. et al.  Prolonged sitting- induced leg endothelial dysfunction is prevented by 
[CONTACT_215497]. Am. J. Physiol. - Hear. Circ. Physiol.  311, H177–H182 (2016). 
11. Restaino, R. M. et al.  Endothelial dysfunction following prolonged sitting is mediated by a 
reduction in shear stress. Am. J. Physiol. - Hear. Circ. Physiol. 310, H648–H653 (2016). 
12. Morishima, T., Restaino, R. M., Walsh, L. K., Kanaley, J. A. & Padilla, J. Prior exercise and standing as strategies to circumvent sitting -induced leg endothelial dysfunction. Clin. 
Sci. (Lond). 131, 1045–1053 (2017). 
13. Ogita, H. & Liao, J. K. Endothelial function and oxidative stress. Endothel. J. Endothel. Cell Res.  11, 123–132 (2004). 
14. Thosar, S. S., Bielko, S. L., Mather, K. J., Johnston, J. D. & Wallace, J. P. Effect of prolonged sitting and breaks in sitting time on endothelial function. Med. Sci . Sports Exerc.  
47, 843–849 (2015). 
15. Thosar, S. S., Bielko, S. L., Wiggins, C. C. & Wallace, J. P. Differences in brachial and femoral artery responses to prolonged sitting. Cardiovasc. Ultrasound 12, 1 –7 (2014). 
16. Chida, Y. & Steptoe, A. Greater cardiovascular responses to laboratory menta l stress are 
associated with poor subsequent cardiovascular risk status: a meta -analysis of prospective 
evidence. Hypertens. (Dallas, Tex.  1979)  55, 1026–32 (2010). 
17. Mehra, V. C., Ramgolam, V. S. & Bender, J. R. Cytokines and cardiovascular disease. J.  
Leukoc. Biol. 78, 805–18 (2005). 
18. Barnes, A. S. The epi[INVESTIGATOR_66240]. Cardiovasc. Dis. women 38, 142 –144 
(2011). 
19. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal. Organ. 102 (2013). doi:978 92 4 1506236 
Page 45 of 45 20. Benjamin, E. J. et al.  Heart Disease and Stroke Statistics’2017 Update: A Report from the 
American Heart Association . Circulation  135, (2017). 
21. Dalgleish, T. et al.  Cardiovascular Disease: A Costly Burden for America Proje ctions 
Through 2035. J. Exp. Psychol. Gen.  136, 23–42 (2007). 
22. Schulz, K. F., Altaian, D. G. & Moher, D. CONSORT 2010 Statement: Updated guidelines 
for reporting parallel group randomized trials. Japanese Pharmacology and Therapeutics  
(2018). 
23. Bowie,  C. R. & Harvey, P. D. Administration and interpretation of the Trail Making Test. 
Nat. Protoc.  (2006). doi:10.1038/nprot.2006.390 
24. Abrahams, S. et al.  Verbal fluency and executive dysfunction in amyotrophic lateral 
sclerosis (ALS). Neuropsychologia (20 00). doi:10.1016/S0028-3932(99)[ZIP_CODE]-3 
25. Hoiland, R. L. et al.  Indomethacin- induced impairment of regional cerebrovascular 
reactivity: Implications for respi[INVESTIGATOR_82817]. J. Physiol. (2015). doi:10.1113/jphysiol.2014.284521 
26. Stone, K. J., Fryer, S. M., Ryan, T. & Stoner, L. The validity and reliability of continuous -
wave near -infrared spectroscopy for the assessment of leg blood volume during an 
orthostatic challenge. Atherosclerosis 251, 234–239 (2016). 
27. Hopkins, W. G., Ma rshall, S. W., Batterham, A. M. & Hanin, J. Progressive statistics for 
studies in sports medicine and exercise science. Med. Sci. Sports Exerc.  41, 3–12 (2009). 
 